BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Hailong Wang, Xiu Xin, Mingzhen Wang, Lingling Han, Jiadai Li, Yao Hao, Congyi Zheng, Chao Shen. Myxovirus resistance protein A inhibits hepatitis C virus replication through JAK-STAT pathway activationArchives of Virology 2018; 163(6): 1429 doi: 10.1007/s00705-018-3748-3
2
Kittirat Glab-ampai, Monrat Chulanetra, Aijaz Ahmad Malik, Thanate Juntadech, Jeeraphong Thanongsaksrikul, Potjanee Srimanote, Kanyarat Thueng-in, Nitat Sookrung, Pongsri Tongtawe, Wanpen Chaicumpa. Human single chain-transbodies that bound to domain-I of non-structural protein 5A (NS5A) of hepatitis C virusScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-14886-9
3
Nikhil Pathak, Mei-Ling Lai, Wen-Yu Chen, Betty-Wu Hsieh, Guann-Yi Yu, Jinn-Moon Yang. Pharmacophore anchor models of flaviviral NS3 proteases lead to drug repurposing for DENV infectionBMC Bioinformatics 2017; 18(S16) doi: 10.1186/s12859-017-1957-5
4
Jason D. Graci, Stephen P. Jung, John Pichardo, Frederick Lahser, Xiao Tong, Zhengxian Gu, Joseph M. Colacino. PTC725, an NS4B-targeting compound, inhibits an HCV genotype 3 replicon, as predicted by genome sequence analysis and determined experimentallyAntimicrobial Agents and Chemotherapy 2016; : AAC.01272-16 doi: 10.1128/AAC.01272-16
5
Islam El-Garawani, Sobhy Hassab El-Nabi, Marwa Gadallah, Eman Abdelsameea. Association between IFN-λ 3 Gene Polymorphisms and Outcome of Treatment with Direct Acting Antivirals in Chronic HCV-Infected Egyptian PatientsImmunological Investigations 2020; : 1 doi: 10.1080/08820139.2020.1722158
6
Sowmya Pattabhi, Courtney R. Wilkins, Ran Dong, Megan L. Knoll, Jeffrey Posakony, Shari Kaiser, Chad E. Mire, Myra L. Wang, Renee C. Ireton, Thomas W. Geisbert, Kristin M. Bedard, Shawn P. Iadonato, Yueh-Ming Loo, Michael Gale, B. Williams. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR PathwayJournal of Virology 2016; 90(5): 2372 doi: 10.1128/JVI.02202-15
7
Mark Nelson, Rafael Rubio, Adriano Lazzarin, Svetlana Romanova, Annie Luetkemeyer, Brian Conway, Jean-Michel Molina, Dong Xu, Subasree Srinivasan, Simon Portsmouth. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected PatientsJournal of Interferon & Cytokine Research 2017; 37(3): 103 doi: 10.1089/jir.2016.0082
8
Florian Douam, Qiang Ding, Alexander Ploss. Recent advances in understanding hepatitis CF1000Research 2016; 5: 131 doi: 10.12688/f1000research.7354.1
9
Joydeep Chakraborty, Eric Hilgenfeldt, Roniel Cabrera. Precision Molecular Pathology of Liver CancerMolecular Pathology Library 2018; : 175 doi: 10.1007/978-3-319-68082-8_10
10
Mingzhen Wang, Yu Wang, Yuehong Liu, Hailong Wang, Xiu Xin, Jiadai Li, Yao Hao, Lingling Han, Fang Yu, Congyi Zheng, Chao Shen, Chiaho Shih. SPSB2 inhibits hepatitis C virus replication by targeting NS5A for ubiquitination and degradationPLOS ONE 2019; 14(7): e0219989 doi: 10.1371/journal.pone.0219989
11
Nicholas A. Meanwell, Ramkumar Rajamani, Paul M. Scola, Li-Qiang Sun. HCV: The Journey from Discovery to a CureTopics in Medicinal Chemistry 2019; 31: 317 doi: 10.1007/7355_2018_58
12
Cloé Comarmond, Patrice Cacoub, David Saadoun. Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antiviralsTherapeutic Advances in Gastroenterology 2020; 13: 175628482094261 doi: 10.1177/1756284820942617
13
Eli Zuckerman, Julio A. Gutierrez, Douglas E. Dylla, Victor de Ledinghen, Andrew J. Muir, Michael Gschwantler, Massimo Puoti, Florin Caruntu, Jihad Slim, Frederik Nevens, Samuel Sigal, Stanley Cohen, Linda M. Fredrick, Ana Gabriela Pires dos Santos, Lino Rodrigues, John F. Dillon. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus InfectionClinical Gastroenterology and Hepatology 2020;  doi: 10.1016/j.cgh.2020.06.044
14
Bettina Zippel-Schultz, Michael Specka, Konrad Cimander, Thomas Eschenhagen, Jörg Gölz, Markus Maryschok, Manfred Nowak, Thomas Poehlke, Heino Stöver, Thomas M. Helms, Norbert Scherbaum. Outcomes of Patients in Long-Term Opioid Maintenance TreatmentSubstance Use & Misuse 2016; 51(11): 1493 doi: 10.1080/10826084.2016.1188946
15
Ellen Childs, Sabrina A. Assoumou, Katie B. Biello, Dea L. Biancarelli, Mari-Lynn Drainoni, Alberto Edeza, Peter Salhaney, Matthew J. Mimiaga, Angela R. Bazzi. Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugsHarm Reduction Journal 2019; 16(1) doi: 10.1186/s12954-019-0286-6
16
Hu Li, Jia-Li Tan, Jian-Rui Li, Nan-Nan Liu, Jin-Hua Chen, Xiao-Qin Lv, Li-li Zou, Biao Dong, Zong-Gen Peng, Jian-Dong Jiang. A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimensBiomedicine & Pharmacotherapy 2019; 116: 108976 doi: 10.1016/j.biopha.2019.108976